一项针对BAG3相关性扩张型心肌病(DCM)成人的AAV基因疗法AFTX-201临床试验 (UPBEAT)
一项评估AFTX-201在患有BCL2相关Athanogene 3(BAG3)突变相关扩张型心肌病的成人参与者中的安全性、耐受性、药效学及初步疗效的1/2期多中心、开放标签、剂量递增和剂量扩展试验:UPBEAT试验
This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation
研究概览
详细说明
Participants will receive a single intravenous infusion of AFTX-201 and will be followed for safety and clinical assessments. The study includes short-term safety monitoring and long-term follow-up for up to 60 months
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Clinical Trials Information
- 电话号码:2 (617) 430-7817
- 邮箱:clinicaltrials@affiniatx.com
学习地点
-
-
Quebec
-
Montreal、Quebec、加拿大、QC H1T 1C8
- 招聘中
- Institut de Cardiologie de Montréal / Montreal Heart Institute
-
接触:
- Jérémie Coordonnateur de recherche EPS / EP research coordinator, BScN
- 电话号码:2293 514-376-3330
- 邮箱:Jeremie.Cortial@icm-mhi.org
-
首席研究员:
- Rafik Tadros, MD
-
-
-
-
Florida
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami Hospital and Clinics
-
接触:
- Lina Carceres
- 电话号码:954 249 3587
- 邮箱:caceresl@miami.edu
-
首席研究员:
- Joshua Hare, MD
-
-
Missouri
-
Kansas City、Missouri、美国、64111
- 招聘中
- St. Lukes Hospital
-
首席研究员:
- Andrew Kao, MD
-
接触:
- Amanda Huffman, RN, BSN
- 电话号码:816-932-0391
- 邮箱:amanda.huffman@bjc.org
-
-
New York
-
New York、New York、美国、10016
- 招聘中
- NYU Langone
-
首席研究员:
- Tajinderpal Saraon, MD
-
接触:
- Loriya Thao
- 电话号码:646-877-6343
- 邮箱:loriya.thao@nyulangone.org
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- Houston Methodist Hospital
-
首席研究员:
- Cindy Martin, MD
-
接触:
- Jennifer (Garrett) Medley Sr. Clinical Trials Manager
- 电话号码:346-238-4516
- 邮箱:jmgarrett@houstonmethodist.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Male or female, 18 to 70 years of age
Truncating mutation in BAG3
Dilated cardiomyopathy with left ventricular ejection fraction (LVEF) < 50% by echocardiogram or cardiac MRI
NYHA Class II or III heart failure symptoms
Body weight ≤ 120 kg
Willing and able to sign informed consent and comply with study procedures
Exclusion Criteria:
Prior myocardial infarction when, in the investigator's judgment, the totality of clinical and imaging evidence supports that left ventricular dysfunction is due to coronary artery disease rather than BAG3-associated dilated cardiomyopathy
Prior heart transplant
Presence or requirement of a left ventricular assist device (LVAD)
IV therapy with positive inotropes, vasodilators, or diuretics for heart failure within 30 days prior to enrollment
Positive neutralizing antibodies to ATC-0187
Any condition that, in the investigator's opinion, would place the subject at undue risk or interfere with study participation or interpretation of results
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:AFTX-201
Participants will receive a single intravenous dose of AFTX-201 |
AFTX-201 is a gene therapy product consisting of the ATC-0187 capsid containing the BCL2-associated Athanogene 3 (BAG3) transgene. It is administered as a single intravenous infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
大体时间:Baseline through 12 months
|
Safety and tolerability of AFTX-201 over 12 months. |
Baseline through 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in pharmacodynamic biomarkers
大体时间:Baseline through 12 months
|
Assessment of the extent of AFTX-201 transduction and myocardial BAG3 protein expression after a single IV dose |
Baseline through 12 months
|
|
Change from baseline in measurement of cardiac function including left ventricular ejection fraction (LVEF)
大体时间:Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on measurement of cardiovascular function |
Baseline through 12 months
|
|
Change from baseline in measurement of cardiac function including peak oxygen consumption (pVO2) by cardiopulmonary exercise test (CPET)
大体时间:Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on measurement of cardiovascular function |
Baseline through 12 months
|
|
Change from baseline in New York Heart Association (NYHA) functional class
大体时间:Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on features of heart failure (HF) including functional classification by New York Heart Association (NYHA) class |
Baseline through 12 months
|
|
Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)
大体时间:Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on quality of life |
Baseline through 12 months
|
|
Change from baseline in NT-proBNP levels through 12 months
大体时间:Baseline through 12 months
|
Assessment of the change from baseline in NT-proBNP levels following a single intravenous dose of AFTX-201 |
Baseline through 12 months
|
|
Change from baseline in NT-proBNP levels during long-term follow-up
大体时间:Baseline through 60 months
|
Assessment of the change from baseline in NT-proBNP levels during long-term follow-up following a single intravenous dose of AFTX-201 |
Baseline through 60 months
|
|
Number of participants with adverse events during long-term follow-up
大体时间:Baseline through 60 months
|
Safety and tolerability of AFTX-201 over 60 months |
Baseline through 60 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.